Exagen Inc. (NASDAQ:XGN) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET

Company Participants

Ryan Douglas - Investor Relations

Ron Rocca - President and Chief Executive Officer

Kamal Adawi - Chief Financial Officer

Mark Hazeltine - Chief Operating Officer

Conference Call Participants

Brian Weinstein - William Blair

Kyle Mikson - Canaccord

Operator

Greetings, ladies and gentlemen, and welcome to the Exagen, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded. I would now like to turn the conference over to our host, Ryan Douglas of Investor Relations for Exagen. Thank you. You may begin, sir.

Ryan Douglas

Good afternoon. Thank you for joining us today. Earlier today, Exagen, Inc. released financial results for the quarter ended March 31, 2022. The release is currently available on the company’s website at www.exogen.com. Ron Rocca, President and Chief Executive Officer; Kamal Adawi, Chief Financial Officer; and Mark Hazeltine, Chief Operating Officer, will host this afternoon’s call.

Before we get started, I’d like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including without limitation statements regarding our business strategy and future financial and operating performance, including 2022 guidance, the impact of the COVID-19 pandemic on our business, our current and future product offerings, distribution and availability and reimbursement and coverage are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

For a list and description of these risks and uncertainties associated with our business, please see our filings with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2021 and subsequent filings. The information provided in this conference call speaks only to the live broadcast today, May 11, 2022. Exagen disclaims any intention or obligation, except as required by law, to update or revise any information, financial projections or other forward-looking statements, whether because of new information, future events or otherwise.